[Famciclovir treatment of patients with chronic hepatitis B virus infection].
OBJECTIVE
To evaluate the effects of famciclovir treatment of patients with chronic hepatitis B virus (HBV) infection.


METHODS
Eighty-nine patients with chronic HBV infection were randomly divided into three groups. Thirty-two patients were treated with famciclovir, 29 patients and 28 patients with chronic HBV infection were treated with interferon (IFN) alpha and lamivudine, respectively, as the control.


RESULTS
The serum HBV DNA became negative after treatment in 40.62% (13/32) of patients treated with famciclovir, 37.93% (11/29) of patients treated with IFN alpha, and 67.90% (19/28) of patients treated with lamivudine. The rate of serum HBeAg loss for the three groups were 21.88% (7/32), 41.38% (12/29) and 21.43% (6/28), respectively. The average time for patients to become serum HBV DNA negative was 1.3 months.


CONCLUSIONS
Famciclovir is an effective and safe nucleoside drug for the treatment of patients with chronic HBV infection.
Li
Li
L
Department No.4, The 302nd Hospital of PLA, Beijing 100039, China.
Shao
Qing
Q
Zhang
Jian
J
Ji
Dong
D
D015075:2-Aminopurine / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000293:Adolescent; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D000077595:Famciclovir; D005260:Female; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome
D000998:Antiviral Agents; D016898:Interferon-alpha; D019259:Lamivudine; D015075:2-Aminopurine; D000077595:Famciclovir